MedTrace Logo

An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma

NCT00738582 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2022-09-22

Study results available
· View outcomes & findings →

Summary

This research is being done to find out if pemetrexed and cisplatin work better when given together with an experimental drug called MORAb-009 in patients with malignant pleural mesothelioma.

Conditions

  • Malignant Pleural Mesothelioma

Interventions

DRUG

MORAb-009 (Amatuximab)

MORAb-009 (Amatuximab) by IV on Days 1 and 8 every 21 days for 6 cycles.

DRUG

Pemetrexed

Pemetrexed 500 mg/m2 on Day 1 of each 21-day cycle for 6 cycles

DRUG

Cisplatin

Cisplatin 75 mg/m2 on Day 1 of each 21-day cycle for 6 cycles

Sponsors & Collaborators

  • Morphotek

    lead INDUSTRY

Principal Investigators

  • Bruce Wallin, MD · Morphotek

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2011-06-30
Completion
2014-01-10
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Germany
  • Netherlands
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00738582 on ClinicalTrials.gov